Patients with genome instability caused by defects in the DNA damage repair response illustrate the detrimental effect of cumulative DNA damage. This includes heightened cancer risk, accelerated aging, and neurodegeneration. A broad spectrum of neurologic manifestations has been associated with disorders of DNA repair, including xeroderma pigmentosum (XP), Cockayne syndrome (CS), ataxia telangiectasia, trichothiodystrophy, and Nijmegen breakage syndrome.^[@R1]^

XP is a rare autosomal recessive disorder arising from deficient DNA repair. XP is caused primarily by mutations in genes encoding components of the nucleotide excision repair (NER) DNA repair pathway. NER recognizes and repairs several types of DNA lesions, including those due to ultraviolet (UV) radiation, which results in bulky dimers at dipyrimidine sites.^[@R2]^ The typical result is sun damage to exposed skin and eyes. Patients with XP have a high frequency of skin cancer in response to genomic damage caused by UV radiation. Approximately one-fourth of patients with XP experience neurologic deterioration, and when present, shortens life expectancy.^[@R3]^ Cumulative toxicity by non--UV-mediated unrepaired genomic lesions in nonreplicating tissue explains neuronal injury.

We report 2 middle-aged Caucasian women with adult-onset chorea, ataxia, dystonia, neuropathy, and later progressive cognitive impairment, but with life-long acute skin sun-burning on minimal sun exposure, freckle-like skin lesions on sun-exposed skin, and early onset of skin cancer in 1 case. Both were found to have compound heterozygous mutations in *ERCC4* and significantly reduced NER capacity, confirming the diagnosis of XP complementation group F (XP-F). Their presentations highlight the importance of adult neurologists considering XP-F when evaluating patients with atypical neurodegeneration.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

Patients were referred by their neurologists to participate in the NIH Undiagnosed Diseases Program (UDP). They enrolled in protocol 76-HG-0238 ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT00369421) approved by the National Human Genome Research Institute (NHGRI) Institutional Review Board. Written informed consent was obtained according to protocol guidelines. Both patients had completed extensive clinical evaluations over the preceding decades, including investigations for toxic, metabolic, infectious, autoimmune, and inflammatory processes and had undergone genetic testing for common inherited adult-onset neurodegenerative disorders. Additional clinical details are summarized in the [table](#T1){ref-type="table"}.

###### 

XP-F patients\' molecular, clinical, and neurologic findings

![](NG2017007278TT1)

Patient 1 {#s1-2}
---------

A now 60-year-old woman of Northern European descent with a history of infertility and skin photosensitivity but no skin neoplasms sought medical attention at the age 46 years with 1 year of progressive memory and balance difficulties. Her skin examination revealed moderate freckling of sun-exposed regions ([figure 1A](#F1){ref-type="fig"}). On neurologic examination, she demonstrated mild chorea of her extremities and face, limb ataxia, absent ankle reflexes, and impaired gait. She had 1 sibling with MS but no other similarly affected relatives ([figure 1B](#F1){ref-type="fig"}). Brain MRI showed severe global atrophy out of proportion to her recent symptom onset ([figure 2, A--D](#F2){ref-type="fig"}). EMG and nerve conduction studies indicated diffuse axonal sensorimotor polyneuropathy. A sural nerve biopsy showed decreased myelinated fibers with clusters of regenerating fibers ([figure 1D](#F1){ref-type="fig"}). Neurologic progression was gradual but relentless over the next 11 years; the patient became dependent on a walker for ambulation and deteriorated in essentially all cognitive domains, with an early Mini-Mental State Examination^[@R4]^ score of 26/30, a Montreal Cognitive Assessment (MoCA)^[@R5]^ score of 18/30 at 6 years, and an MoCA score of 16/30 at 8 years after her initial visit.

![Two cases of XP-F with adult-onset neurologic deterioration\
Patient 1 (top): panels (A--D) and patient 2 (bottom): panels (E--G). (A and E) Face photographs of patients 1 and 2 demonstrating prominent skin freckling (patient 1) or scarring (open arrows) at the sites of prior basal cell carcinoma resections (patient 2). (B and F) Nuclear family pedigrees for patient 1 (UDP_3675) and patient 2 (UDP_7356). (C and G) Sanger chromatogram for patient 1 and patient 2 demonstrating relevant mutations in both *ERCC4* alleles (arrows). (D) Representative image of sural nerve biopsy (embedded in Epon and stained with toluidine blue) from patient 1 demonstrating a decrease in the number of myelinated fibers with evidence of degeneration/regeneration clusters (×400). (H) Measurement of UDS in patient fibroblasts. Values are normalized to those obtained for NER-proficient (C5RO) and NER-deficient (XP51RO) control fibroblasts.^[@R8]^ Cells were irradiated with 24 J/m^2^ UV and then incubated in the presence of the thymidine analog EdU for 2.5 hours to allow DNA repair. AlexaFluor647 was conjugated to EdU by Click-iT chemistry before fixation, stained with DAPI, and quantification of the fluorescence signal in G1 cells measured by flow cytometry. UDS was measured in duplicate for each cell line in 3 independent experiments. Values represent mean ± SD, \*\*\*\**p* \< 0.0001 by 1-way ANOVA.](NG2017007278FF1){#F1}

![Representative axial and sagittal sections of T1-weighted brain MRIs\
Patient 1 (top, A--D) and patient 2 (bottom, E--H) demonstrate prominent and diffuse atrophy in the supra- and infra-tentorial compartments.](NG2017007278FF2){#F2}

Patient 2 {#s1-3}
---------

A 52-year-old woman of Ashkenazi Jewish descent presented with a 20-year history of progressive dystonia, gait ataxia, hearing loss, and worsening cognition. Her past medical history included photosensitivity with blistering skin lesions after limited sun exposure resulting in multiple facial lentigines and basal cell carcinomas as a teenager. Because of aggressive photoprotection, she had minimal freckling but multiple scars from basal cell carcinoma resections ([figure 1E](#F1){ref-type="fig"}). There was a maternal history of mild postural tremor but no similarly affected relatives ([figure 1F](#F1){ref-type="fig"}). On neurologic examination, the patient was disoriented, partly amnestic, and struggled to follow simple commands. She had dystonic and choreiform movements of the head and neck, a coarse, irregular appendicular tremor, ataxia, and spasticity and was using a wheelchair. She had brisk reflexes and upgoing toes. Brain MRI demonstrated global cerebral atrophy and inner table hyperostosis ([figure 2, E--H](#F2){ref-type="fig"}). There was no electrophysiologic evidence of polyneuropathy. The patient died at age 54 years from secondary medical complications.

Results {#s2}
=======

Following singleton whole-exome sequencing, variants were prioritized based on known disease association, population frequency, and various in-silico pathogenicity models. Both patients had compound heterozygous mutations in *ERCC4* ([table](#T1){ref-type="table"}). Patient 1 ([figure 1C](#F1){ref-type="fig"}) carried 2 known *ERCC4* mutations associated with XP-F; NM_005236.2: c.1765C\>T; p.Arg589Trp and c.2395C\>T,p.Arg799Trp.^[@R6],[@R7]^ Patient 2 ([figure 1G](#F1){ref-type="fig"}) had the p.Arg799Trp allele and an ultra-rare *ERCC4* truncating mutation; NM_005236.2:c.1376C\>A, p.Ser459\*. Segregation analysis of the families confirmed compound heterozygous allele pairs in both.

NER capacity was investigated by measuring unscheduled DNA synthesis (UDS) determining the incorporation of nucleotides into the nuclear genome of nonreplicating, UV-C irradiated patient-derived fibroblasts (see figure 1 legend for details). The percent repair was obtained by comparing irradiated and unirradiated patient cells to reference standards NER-proficient human fibroblasts (C5RO) and NER-deficient human fibroblasts (XP51RO). XP51RO cells were from a patient with a homozygous p.Arg153Pro *ERCC4* mutation associated with a phenotype of XFE progeroid syndrome and severely reduced (\<3%) UDS.^[@R8]^ UDS of fibroblasts from patients 1 and 2 had 26.0% ± 4.8% and 21.3% ± 5.1% of the expected NER capacity, respectively, indicating significant NER impairment ([figure 1H](#F1){ref-type="fig"}).

Discussion {#s3}
==========

The prevalence of XP in the general population approximates 1 in 1 million, being higher in Japan because of a founder mutation in XPA. One-fourth of individuals with XP exhibit neurologic manifestations including acquired microcephaly, neuropathy, sensorineural hearing loss, and progressive cognitive impairment. In a long-term follow-up study of 89 patients with XP in the United Kingdom, three patients were diagnosed with XP-F, one of whom demonstrated neurologic features similar to our patients.^[@R9]^ Up to 10% of all XP is XP-F.^[@R3],[@R10]^ XP-F is caused by mutations in the *ERCC4* gene. The encoded ERCC4/XPF protein forms a tight complex with the ERCC1 protein. This heterodimer provides 5′-nuclease activity for a crucial excision step of NER.^[@R2]^

Compared with other XP subtypes, patients with XP-F have less propensity for skin neoplasms and present later, often past the 4th decade.^[@R10]^ Neurodegeneration is largely reported in younger patients in complementation groups XP-A, XP-B, XP-D, and XP-G but not in XP-C or XP-E and is often heralded by progressive neurosensory hearing loss.^[@R3]^ Neurologic features reported in XP-F include gait disturbances, ataxia, neuropathy, chorea, sensorineural hearing loss, cognitive decline, and cerebral and cerebellar atrophy.^[@R6],[@R7],[@R10]^ Our observations support reports suggesting that *ERCC4*: p.Arg799Trp might be a common allele among XP-F patients with adult-onset neurodegeneration.^[@R6]^ Besides XP-F, *ERCC4* mutations are associated with other diseases, including XFE progeria with very low UDS, Fanconi Anemia, and XP/CS.^[@R3],[@R8]^

Like other reported XP-F cases with neurodegeneration, our patients manifested disparity between severity of brain atrophy by MRI at the time of first imaging and relatively modest early cognitive deficits, consistent with compensation of a very slow neurodegenerative process over decades. This contrasts with other neurodegenerative disorders, such as Alzheimer disease, in which profound impairment usually accompanies such severe degree of brain atrophy.

These cases elicit consideration of several points. First, dysfunction of the NER pathway can be associated with profound neurodegeneration. Second, there is a causal role of cumulative unrepaired DNA damage in neurodegenerative disorders in general. The precise type of damage leading to neurodegeneration is unclear but may relate to stable oxidative genomic lesions. Finally, the diagnosis of XP, and particularly XP-F, should be considered in adult patients with unexplained neurodegeneration associated with global brain atrophy, especially when accompanied by a history of photosensitivity, skin malignancies, and/or excessive freckling.
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